Immunotherapy in the treatment of non-small cell lung cancer - Wikidata - awgldk - TriplyDB

Immunotherapy in the treatment of non-small cell lung cancer

Immunotherapy in the treatment of non-small cell lung cancer

http://www.wikidata.org/entity/Q27000382

about

Immunotherapy for lung cancer: advances and prospects Cancer stem cells and immunoresistance: clinical implications and solutions Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups Molecular Role of EGFR-MAPK Pathway in Patchouli Alcohol-Induced Apoptosis and Cell Cycle Arrest on A549 Cells In Vitro and In Vivo.Lung cancer research is taking on new challenges: knowledge of tumors' molecular diversity is opening new pathways to treatment.Immune checkpoint inhibitors in clinical trials Prognostic value of preoperative absolute lymphocyte count in recurrent hepatocellular carcinoma following thermal ablation: a retrospective analysis Nivolumab in NSCLC: latest evidence and clinical potential Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis The action and mechanism of myrislignan on A549 cells in vitro and in vivo.Decreased Interferon Alpha/Beta Signature Associated with Human Lung Tumorigenesis.Shedding light on the molecular determinants of response to anti-PD-1 therapy B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer.Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer.Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues.The management of brain metastases in non-small cell lung cancer.The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?Targeting the immune system to treat lung cancer: rationale and clinical experience.Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium.Best practice in the treatment of advanced squamous cell lung cancer.Assays for predicting and monitoring responses to lung cancer immunotherapy.Apoptosis of Lewis Lung Carcinoma Cells Induced by Microwave via p53 and Proapoptotic Proteins In vivo.Lung Cancer Staging and Prognosis.Nivolumab in Metastatic Non-Small Cell Lung Cancer.LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses.Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.Docosahexaenoic Acid Induces Cell Death in Human Non-Small Cell Lung Cancer Cells by Repressing mTOR via AMPK Activation and PI3K/Akt Inhibition.Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples.Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis.Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature

P2860

Q26750617-E6817009-9974-4642-B047-3501418FE42C Q26769757-864C26A8-4267-4B4E-B904-2833CF245AE1 Q26852206-B108DAA3-1CFA-4285-87A9-0E3D61AD2A52 Q27853205-7CA90205-C4B6-4F60-840C-0EF5294824CC Q32186320-9E187192-EE6D-45CD-900D-965807758A3F Q34306441-FDF1FE4E-2F7D-436C-97F7-6C6891DDD7BB Q34309394-DFDE5F3B-32A4-444E-88C3-6B22EEA08E52 Q34352741-AB58E1AB-9093-4F09-9EDA-450345C508AF Q34466452-A8980B31-4659-48DF-9C36-92264C466BBF Q35290679-0A01EDC6-D3C1-459E-8807-AC10AADF77B8 Q36095323-005A8FB5-A0DD-4A05-A515-55D1B2E4522C Q36382859-4AD36797-9511-4780-A27B-4131F0A0A5E0 Q36427373-24C67E8D-BBE1-46F8-BD37-DEA34146CF0B Q36464312-31ADED3F-8C62-4691-8CE8-59A3BBD89123 Q36689140-A16F7B47-23D3-404A-9015-E7035CC16BF8 Q36821194-7F54A459-5B52-4231-95AE-7AD95FACE679 Q37087884-19118C63-958D-4241-A573-3CE533359B23 Q37606871-1D3280FA-F280-4539-95A3-9C0FF303A55E Q38257364-0B216BA1-D3F7-4C99-844B-8F5BEFA61077 Q38259586-8A332482-3E6D-40B5-BA4F-9DC445B4C782 Q38264982-0F0587ED-8F0B-47F6-BAB4-FDEE8994C8AE Q38358410-321C624C-A7C9-4C65-972F-568CA75AB78C Q38366141-727D6DD6-D4D4-45C6-B11A-DBF5D039E26F Q38397629-2134CE57-3378-4D4A-BEA6-87D4343BCF0F Q38435403-504AF5BA-CF4D-4C9C-8D00-F839282DC882 Q38435967-46A08788-3DFC-48FF-B00E-C42026A611DE Q38547391-4F5DC659-D123-45C6-BC5E-48B45B23DE92 Q38723069-AA2B17B1-47C8-4C1B-9150-80F538020C2B Q38830349-6DE215E2-AC3E-4F5A-B78B-9737B7CF9122 Q39089957-9169C787-16CA-46D9-9DB1-0E7DD139F095 Q39748865-BFB2A527-DEB1-4205-AA22-FFA84B845DFB Q40244187-EA35E121-E09E-43E2-80E8-2D3E215FD222 Q40424521-E59561CC-428C-43D3-AFDD-E2B52A1ADD8A Q40574345-195269E2-19C4-4177-8A94-51CB9F201518 Q41302377-49B6B5CF-ED9E-4381-B7FD-9BE33D376611 Q47714757-B346BE6F-D43C-4D0F-8496-55AD236CB4AC Q50347895-777018D6-D0D3-4BF2-A7ED-7FBDD82A0059 Q50634571-B7A02498-12C1-4C9A-B986-39D22AC8DDCB Q55440274-9E060A3B-F991-4D04-9461-66DA3F5F7C0F Q57298272-54EA0772-D455-42A0-8D5E-9437C6D42D30

P2860

Immunotherapy in the treatment of non-small cell lung cancer

http://www.wikidata.org/entity/Q27000382

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Immunotherapy in the treatment of non-small cell lung cancer

@ast

Immunotherapy in the treatment of non-small cell lung cancer

@en

Immunotherapy in the treatment of non-small cell lung cancer

@nl

type

label

Immunotherapy in the treatment of non-small cell lung cancer

@ast

Immunotherapy in the treatment of non-small cell lung cancer

@en

Immunotherapy in the treatment of non-small cell lung cancer

@nl

prefLabel

Immunotherapy in the treatment of non-small cell lung cancer

@ast

Immunotherapy in the treatment of non-small cell lung cancer

@en

Immunotherapy in the treatment of non-small cell lung cancer

@nl

P1433

Q27000382-2C131A9E-C4E6-4B42-95D9-2961C1E3806D

P1476

Q27000382-09E6766F-3B36-4D92-A0EC-1A805945D9EA

P2093

Q27000382-20D7876E-1D77-4987-BBB3-8473C95B7A54

Q27000382-A28C2E25-48DA-40C5-AB30-9E9AF2DE6C84

P2860

Q27000382-044CC2C6-6348-4DB1-AEBB-4DF19A36ACC3

Q27000382-0B4B9EB5-A145-449B-955D-4696B9A21D84

Q27000382-0BB02ED3-92BF-4093-A9AF-2F2AC6107319

Q27000382-12AB6DED-F3C3-49CD-A33A-EF6F096E37BC

Q27000382-1434F13A-495C-472C-8BB0-DDBC4500498B

Q27000382-1C24C2FD-2F8C-44F1-839E-FF12F1137ED0

Q27000382-1EDA64BC-E102-4CFA-BE7E-EFE2CFAAC4D8

Q27000382-212FDAAD-CAFE-4CED-A12F-2B1D5E65EAF5

Q27000382-21792ED3-6ABC-4C5A-A7AC-2AC71400D240

Q27000382-273EBDC2-A522-4A6C-AB1D-45288D0FE5F0

P304

Q27000382-94AC986B-651B-4E0B-BCA2-5D1567646739

P31

Q27000382-199AA7BB-D73F-437C-ACA3-B63718074674

P3181

Q27000382-C4B23FD8-9140-474A-A48D-9B9DDCEF13FF

P356

Q27000382-43FAB697-4E2F-4E66-A0E6-8714A6AB997D

P407

Q27000382-9130F8C5-5D16-4C12-B474-AE029C06BB80

P433

Q27000382-40C006F1-7E0F-4873-A7EB-3CF15315153A

P478

Q27000382-B1F8C6D6-0CDC-46DE-B69A-160640FA8080

P50

Q27000382-3AE7D411-D140-40B7-854F-40CFDD78CF43

Q27000382-885BAD9D-F450-4DCD-A3C1-CB3F8454120E

Q27000382-99A13ED1-1B05-4E54-8134-74C480A82C14

P577

Q27000382-C7210642-7A61-439D-97EB-5DA52461D4F3

P5875

Q27000382-FC1AC117-539D-44F4-8FEC-2DEAF98AFCC1

P698

Q27000382-9D945591-D5C5-4845-BD4D-26A032625D25

P921

Q27000382-FA20B974-54C9-496F-8BCC-74F5D9FD2612

P932

Q27000382-3A71CDC1-91B3-4EED-9676-75774E42807C

P3181

P356

J.LUNGCAN.2014.05.005

P1433

P1476

Immunotherapy in the treatment of non-small cell lung cancer

@en

P2093

Julie R Brahmer

http://www.w3.org/2001/XMLSchema#string

Ross A Soo

http://www.w3.org/2001/XMLSchema#string

P2860

Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

Global cancer statistics

Hallmarks of Cancer: The Next Generation

CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

P304

101-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2945922

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.LUNGCAN.2014.05.005

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

Byoung Chul Cho

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262306856

http://www.w3.org/2001/XMLSchema#string

P698

24880938

http://www.w3.org/2001/XMLSchema#string

P921

P932

4332778

http://www.w3.org/2001/XMLSchema#string